China approves iBio's iBioModulator technology for use against influenza
This new approval allows iBio to expand its territories. It is currently approved in the U.S. under Patent 8,124,103 titled "Influenza Antigen, Vaccine Compositions and Related Methods."
"China, by virtue of the scale of its rapidly-emerging domestic market and need for new biopharmaceutical technology infrastructure to address influenza and other emerging infectious disease threats, is a target market for us," President of iBio Robert Erwin said. "This new intellectual property protection will further facilitate our ability to license our technology for the Chinese market."
iBioModular technology fuses Lichenase proteins to antigens, which acts as an adjuvant and enhances the length of an immune response, making a vaccine more effective. In trials with iBioModular technology, higher performance was seen from antigens from plague, malaria and human papilloma virus.
The iBioModulator technology both increases the initial immune response and extends the duration of that response. This means the dose and antigen requirements of a vaccine can be lowered due to better and longer immune responses with the use of this technology.
In the case of China, iBio said the overall cost and difficulties of administering immunizations decrease with the use of its technology.